Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (161-170 of 208) with videos related to

Pageof 21
Sort By:
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.
Frontiers in Oncology|August 22, 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLCRachel Evans, Kelvin Lee, Paul K Wallace, et al.
Journal of Translational Medicine|November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditisIgor Puzanov, Poornima Subramanian, Yan V Yatsynovich, et al.
Journal of Translational Medicine|July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Journal of Translational Medicine|September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Pageof 21

Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.
Frontiers in Oncology|August 22, 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLCRachel Evans, Kelvin Lee, Paul K Wallace, et al.
Journal of Translational Medicine|November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditisIgor Puzanov, Poornima Subramanian, Yan V Yatsynovich, et al.
Journal of Translational Medicine|July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Journal of Translational Medicine|September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Pageof 21